Literature DB >> 16884811

Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy.

I Krass1, B Mitchell, P Clarke, M Brillant, R Dienaar, J Hughes, P Lau, G Peterson, K Stewart, S Taylor, J Wilkinson, C Armour.   

Abstract

OBJECTIVE: To compare the efficacy and cost-effectiveness of two methods of screening for undiagnosed type 2 diabetes in Australian community pharmacy.
METHODS: A random sample of 30 pharmacies were allocated into two groups: (i) tick test only (TTO); or (ii) sequential screening (SS) method. Both methods used the same initial risk assessment for type 2 diabetes. Subjects with one or more risk factors in the TTO group were offered a referral to their general practitioner (GP). Under the SS method, patients with risk factors were offered a capillary blood glucose test and those identified as being at risk referred to a GP. The effectiveness and cost-effectiveness of these approaches was assessed.
RESULTS: A total of 1286 people were screened over a period of 3 months. The rate of diagnosis of diabetes was significantly higher for SS compared with the TTO method (1.7% versus 0.2%; p=0.008). The SS method resulted in fewer referrals to the GP and a higher uptake of referrals than the TTO method and so was the more cost-effective screening method.
CONCLUSIONS: SS is the superior method from a cost and efficacy perspective. It should be considered as the preferred option for screening by community based pharmacists in Australia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884811     DOI: 10.1016/j.diabres.2006.06.022

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  20 in total

1.  Clinical services for obstructive sleep apnea patients in pharmacies: the Australian experience.

Authors:  Carissa A Hanes; Keith K H Wong; Bandana Saini
Journal:  Int J Clin Pharm       Date:  2014-02-23

2.  Screening and identifying diabetes in optometric practice: a prospective study.

Authors:  Jennifer H Howse; Steve Jones; A Pali S Hungin
Journal:  Br J Gen Pract       Date:  2011-07       Impact factor: 5.386

3.  The roles of community pharmacists in cardiovascular disease prevention and management.

Authors:  J George; K McNamara; K Stewart
Journal:  Australas Med J       Date:  2011-05-31

4.  Quality Control of Norwegian Pharmacy HbA1c Testing: A Modest Beginning.

Authors:  Una Ørvim Sølvik; Aslaug Johanne Risøy; Reidun L S Kjome; Sverre Sandberg
Journal:  J Diabetes Sci Technol       Date:  2018-04-05

5.  Patient satisfaction with a chronic kidney disease risk assessment service in community pharmacies.

Authors:  Pankti A Gheewala; Gregory M Peterson; Syed Tabish R Zaidi; Matthew D Jose; Ronald L Castelino
Journal:  Int J Clin Pharm       Date:  2018-02-13

6.  Diabetes care in Norwegian pharmacies: a descriptive study.

Authors:  Reidun L S Kjome; Sverre Sandberg; Anne Gerd Granås
Journal:  Pharm World Sci       Date:  2007-09-22

7.  The development of a sleep disorder screening program in Australian community pharmacies.

Authors:  Adam Tran; Joanne M Fuller; Keith K Wong; Ines Krass; Ron Grunstein; Bandana Saini
Journal:  Pharm World Sci       Date:  2009-05-22

8.  Cardiovascular disease risk prevention services by pharmacists in Saudi Arabia: what do policymakers and opinion leaders think?

Authors:  Hadi A Almansour; Nouf M Aloudah; Tariq M Alhawassi; Betty Chaar; Ines Krass; Bandana Saini
Journal:  J Pharm Policy Pract       Date:  2021-05-06

9.  Development, validation and implementation of continuous professional development programmes for community pharmacists.

Authors:  R Adepu; A Shariff
Journal:  Indian J Pharm Sci       Date:  2010-09       Impact factor: 0.975

10.  The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting.

Authors:  Andrew Willis; Peter Rivers; Laura J Gray; Melanie Davies; Kamlesh Khunti
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.